-+ 0.00%
-+ 0.00%
-+ 0.00%

KEYTRUDA® (PEMBROLIZUMAB) AS MONOTHERAPY REDUCED THE RISK OF DISEASE PROGRESSION OR DEATH BY 43% FOR CERTAIN PATIENTS WITH ADVANCED OR RECURRENT ENDOMETRIAL CANCER WITH MISMATCH REPAIR DEFICIENT (DMMR) TUMORS COMPARED TO CHEMOTHERAPY

Reuters·10/26/2026 15:35:00

Please log in to view news